Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of microRNA-based oncology therapeutics. The company is developing mimics of naturally occurring microRNAs (miR) that are designed to restore tumor suppressor activity and aid appropriate anti-tumor immune response. Its lead product candidate is MRX34, a mimic of naturally occurring microRNA-34 encapsulated in a liposomal nanoparticle formulation which is in Phase 1 clinical trial for the treatment of cancer. The company’s preclinical product candidates include miR-215 for the treatment of esophageal, kidney, and multiple myeloma cancers; miR-101 for the treatment of bladder, gastric, lung, and ovarian cancers; miR-16 for the treatment of chronic lymphocytic leukemia and lymphoma cancers; and let-7 for the treatment of prostate, pancreatic, and melanoma cancers. It has strategic partnerships and license agreements with Asuragen, Inc.; Marina Biotech, Inc.; the Yale University; the University of Zurich; Rosetta Genomics Ltd.; the Cancer Prevention and Research Institute of Texas; and Polymun Scientific Immunbiologische Forschung GmbH. The company was founded in 2007 and is headquartered in Austin, Texas. Mirna Therapeutics, Inc. operates as a subsidiary of Asuragen, Inc.